Y-box binding protein 1 augments sorafenib resistance via the PI3K/Akt signaling pathway in hepatocellular carcinoma

BACKGROUND: Sorafenib is the first-line treatment for patients with advanced hepatocellular carcinoma (HCC). Y-box binding protein 1 (YB-1) is closely correlated with tumors and drug resistance. However, the relationship between YB-1 and sorafenib resistance and the underlying mechanism in HCC remai...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ting, Xie, Xiao-Li, Zhou, Xue, Chen, Sheng-Xiong, Wang, Yi-Jun, Shi, Lin-Ping, Chen, Shu-Jia, Wang, Yong-Juan, Wang, Shu-Ling, Zhang, Jiu-Na, Dou, Shi-Ying, Jiang, Xiao-Yu, Cui, Ruo-Lin, Jiang, Hui-Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Basic Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326262/
https://www.ncbi.nlm.nih.gov/pubmed/34366628
http://dx.doi.org/10.3748/wjg.v27.i28.4667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326262/
https://www.ncbi.nlm.nih.gov/pubmed/34366628
http://dx.doi.org/10.3748/wjg.v27.i28.4667

Ejemplares similares